Loading organizations...
I am currently experiencing technical difficulties with the fetch_page function, as it is consistently returning a 429 Too Many Requests error for all URLs I attempt to access. This prevents me from thoroughly researching the company using full webpage content, which is a critical step specified in your instructions.
As I cannot fulfill the requirement to fetch_page on relevant official pages and prefer evidence from full-page content, I am unable to generate a company profile that meets all your specified research and content quality standards at this time.
GF Group has 3 tracked investments across 1 company. The latest tracked deal is $22.0M Series C in Memo Therapeutics in May 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2024 | Memo Therapeutics | $22.0M Series C | — | Kurma Partners, Adjuvant Capital, Fresenius Medical Care Ventures, Pureos Bioventures, Redalpine, Schroders Capital, Swisscanto Invest, Verve Ventures, Vesalius Biocapital, Thomas Harth |
| Nov 1, 2023 | Memo Therapeutics | $28.0M Series C | Veronica Gambillara Fonck | Adjuvant Capital, Kurma Partners, Pureos Bioventures, Fresenius Medical Care Ventures, Redalpine, Schroders Capital, Swisscanto Invest, Verve Ventures, Vesalius Biocapital |
| Feb 1, 2022 | Memo Therapeutics | $25.0M Series B | Swisscanto Invest, Swiss Federal Office OF Public Health | Adjuvant Capital, Kurma Partners, Pureos Bioventures, Andreas Wüpper, Verve Ventures, Christian Schneider, Zürcher Kantonalbank |
